TD Asset Management
ORIC icon

TD Asset Management’s Oric Pharmaceuticals ORIC Stock Holding History

TD Asset Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.66M Sell
246,002
-12,600
-5% -$114K ﹤0.01% 919
2026
Q1 		$3.28M Buy
258,602
+88,772
+52% +$1.01M ﹤0.01% 870
2025
Q4 		$1.39M Buy
169,830
+18,130
+12% +$209K ﹤0.01% 1055
2025
Q3 		$1.82M Sell
151,700
-26,000
-15% -$274K ﹤0.01% 992
2025
Q2 		$1.8M Buy
177,700
+25,000
+16% +$168K ﹤0.01% 966
2025
Q1 		$852K Buy
152,700
+4,900
+3% +$42.8K ﹤0.01% 1096
2024
Q4 		$1.19M Buy
147,800
+8,400
+6% +$77.1K ﹤0.01% 1093
2024
Q3 		$1.48M Hold
139,400
– – ﹤0.01% 1121
2024
Q2 		$986K Sell
139,400
-69,200
-33% -$619K ﹤0.01% 1161
2024
Q1 		$2.87M Buy
208,600
+127,800
+158% +$1.52M ﹤0.01% 913
2023
Q4 		$743K Buy
+80,800
New +$584K ﹤0.01% 1242

Other funds holding ORIC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIHC Capital Management Central $104M AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TD Asset Management's ORIC Position: Q2 2026 in Review

TD Asset Management reduced its Oric Pharmaceuticals (ORIC) stake by 4.9% in Q2 2026, selling an estimated $114K and leaving 246,002 shares worth $2.66M. The position accounts for ﹤0.01% of the portfolio, ranked #919.

TD Asset Management first reported a position in ORIC in Q4 2023 and has held it in 11 quarters since. The position peaked at $3.28M in Q1 2026. 103 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • TD Asset Management held 246,002 shares of Oric Pharmaceuticals worth $2.66M as of Q2 2026.
  • TD Asset Management sold 12,600 Oric Pharmaceuticals shares in Q2 2026, an estimated $114K.
  • Oric Pharmaceuticals made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #919 holding.
  • TD Asset Management first reported a position in Oric Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • TD Asset Management's Oric Pharmaceuticals position peaked at $3.28M in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.